| Date | Time | Source | |
| 05/16/2013 | 10:00AM | ZACKS | Pipeline Progress at Gilead - Analyst Blog
Gilead Sciences, Inc. (GILD) recently presented encouraging data on its pipeline candidate idelalisib (formerly GS-1101) from a phase II study (study 101-08: n=64). The study is evaluating idelalisib combined with Roche Holding AG’s (RHHBY) Rituxan/MabThera (rituximab) in treatment-naïve patients (aged ≥65... More...>> |
| 05/15/2013 | 1:20PM | ZACKS | Cempra/Toyama Ink Deal - Analyst Blog
Cempra, Inc. (CEMP) recently entered into an exclusive license and development agreement with a Japanese company, Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings (FUJIY) for an antibiotic candidate, solithromycin (formerly known as CEM -101). As per the terms of the agreement, Cempra has licensed Toyama Chemical... More...>> |
| 05/15/2013 | 1:20PM | ZACKS | Cempra/Toyama Ink Deal - Analyst Blog
Cempra, Inc. (CEMP) recently entered into an exclusive license and development agreement with a Japanese company, Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings (FUJIY) for an antibiotic candidate, solithromycin (formerly known as CEM -101). As per the terms of the agreement, Cempra has licensed Toyama Chemical... More...>> |
| 05/15/2013 | 7:21AM | ZACKS | Synergy Pharma Posts Wider Loss - Analyst Blog
Synergy Pharmaceuticals Inc. (SGYP) reported a loss of 24 cents per share in the first quarter of 2013, wider than the year-ago loss of 13 cents and the Zacks Consensus Estimate of a loss of 17 cents per share. The wider loss during the quarter was primarily due to higher expenses. Synergy Pharma did not generate any revenues... More...>> |
| 05/15/2013 | 6:00AM | ZACKS | Wider-Than-Expected Loss at Athersys - Analyst Blog
Athersys, Inc.’s (ATHX) first quarter 2013 adjusted net loss of 13 cents per share was wider than the Zacks Consensus Estimate of a loss of 10 cents. Lower-than-expected revenues were primarily responsible for the wider-than-expected loss. The company suffered an adjusted loss of 19 cents per share in the year-ago... More...>> |
| 05/14/2013 | 8:43AM | ZACKS | Celgene Attains 52-Week High - Analyst Blog
Shares of Celgene Corporation (CELG) hit a 52-week high of $131.13 in the first half of the trading session on May 13. This biopharmaceutical stock gained significant momentum following its strong performance in the first quarter of 2013 last month. The reaffirmation of the rosy long-term outlook coupled with the impressive... More...>> |
| 05/14/2013 | 5:23AM | ZACKS | NPS Pharma Incurs Narrower 1Q Loss - Analyst Blog
NPS Pharmaceuticals, Inc. (NPSP) reported first quarter 2013 net loss per share of 9 cents per share, narrower than the Zacks Consensus Estimate of a loss of 13 cents and the year-ago loss of 12 cents. The narrower loss was primarily attributable to higher revenues. First quarter 2013 revenues climbed 11% to $25.4 million... More...>> |
| 05/13/2013 | 2:06PM | ZACKS | Setback for Endo Health on Opana ER - Analyst Blog
Endo Health Solutions Inc. (ENDP) recently suffered a setback with the US Food and Drug Administration (FDA) turning down its request to prevent the entry of generic versions of the company’s painkiller Opana ER. We remind investors that Endo had filed a Citizen Petition (CP) with the FDA in 2012. Through the CP... More...>> |
| 05/13/2013 | 5:48AM | ZACKS | Earnings Beat at Warner Chilcott - Analyst Blog
Warner Chilcott’s (WCRX) first quarter 2013 earnings (excluding special items) of 92 cents per share handsomely beat the Zacks Consensus Estimate of 85 cents. Lower selling, general & administrative costs boosted earnings in the reported quarter. The company earned $1.16 per share in the first quarter of 2012. ... More...>> |
| 05/13/2013 | 5:11AM | ZACKS | Narrower-than-Expected Loss at MannKind - Analyst Blog
MannKind Corporation’s (MNKD) loss of 15 cents per share in the first quarter of 2013 was narrower than the Zacks Consensus Estimate of a loss of 16 cents and the year-ago loss of 27 cents per share. Quarter in Detail MannKind did not generate any revenue in the first quarter of 2013 as in the year-ago quarter. Research... More...>> |
| 05/10/2013 | 8:10AM | ZACKS | Wider-than-Expected Loss at Optimer - Analyst Blog
Optimer Pharmaceuticals Inc.’s (OPTR) first quarter 2013 net loss (excluding special items) of 65 cents per share was wider than the Zacks Consensus Estimate of a loss of 42 cents but narrower than the year-ago loss of 73 cents per share. Lower-than-expected revenues were primarily responsible for the wider-than-expected... More...>> |
| 05/09/2013 | 11:53AM | ZACKS | Good News for Cubist Pharmaceuticals - Analyst Blog
Cubist Pharmaceuticals, Inc. (CBST) recently received encouraging news when the US Food and Drug Administration (FDA) granted the company’s antibiotic candidate ceftolozane/tazobactam (CXA-201) a fast track status in Qualified Infectious Disease Product (QIDP) indications, under the Generating Antibiotic Incentives... More...>> |
| 05/08/2013 | 5:24PM | BW | Cubist to Present at Bank of America Merrill Lynch 2013 Healthcare Conference
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that Robert Perez, Cubist’s President and COO, will present at the Bank of America Merrill Lynch 2013 Healthcare Conference on Wednesday, May 15, to discuss the company’s business activities, financial outlook, and current news. The conference will be held... More...>> |
| 05/08/2013 | 1:36PM | ZACKS | Earnings Beat at Endo Health, Sales Slip - Analyst Blog
Endo Health Solutions’ (ENDP) first quarter 2013 earnings (excluding special items) of $1.09 per share beat the Zacks Consensus Estimate by a penny and increased 25% from the year-ago period. Earnings in the first quarter of 2013 were aided by lower costs. Revenues came in at $708.5 million in the first quarter of... More...>> |
| 05/07/2013 | 12:00PM | ZACKS | Positive Data on Forest Combo Drug - Analyst Blog
Forest Laboratories, Inc. (FRX) and Almirall, S.A. recently announced positive top-line data on their chronic obstructive pulmonary disease (COPD) fixed dose combination candidate, aclidinium bromide (LAMA) and formoterol fumarate (LABA). Two fixed dose combinations – aclidinium/formoterol (400/6mcg and 400/12mcg... More...>> |
| 05/07/2013 | 12:00PM | ZACKS | Positive Data on Forest Combo Drug - Analyst Blog
Forest Laboratories, Inc. (FRX) and Almirall, S.A. recently announced positive top-line data on their chronic obstructive pulmonary disease (COPD) fixed dose combination candidate, aclidinium bromide (LAMA) and formoterol fumarate (LABA). Two fixed dose combinations – aclidinium/formoterol (400/6mcg and 400/12mcg... More...>> |
| 05/07/2013 | 8:30AM | BW | FDA Grants Fast Track Designation for Cubist’s Late-Stage Antibiotic Candidate
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company’s late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously granted Qualified Infectious Disease Product (QIDP) indications, Hospital-Acquired... More...>> |
| 05/07/2013 | 4:25AM | ZACKS | Alnylam Narrows Loss, Sales Fall - Analyst Blog
Alnylam Pharmaceuticals Inc.’s (ALNY) first quarter 2013 loss of 15 cents per share was narrower than the Zacks Consensus Estimate of a loss of 31 cents and the year-ago loss of 25 cents per share. The narrower loss was primarily due to lower expenses. Quarter in Detail Revenues for the reported quarter fell 9.4... More...>> |
| 05/06/2013 | 8:02AM | ZACKS | Teva Beats on Earnings, Revenues - Analyst Blog
Teva Pharmaceutical Industries (TEVA) reported first quarter earnings of $1.12 per American Depositary Share (ADS), a couple of cents above the Zacks Consensus Estimate but 23.8% below the year-ago earnings. First quarter revenues declined 3.9% to $4.9 billion, just above the Zacks Consensus Estimate of $4.8 billion. The... More...>> |
| 04/19/2013 | 7:00AM | DJN | U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH
Among the companies with shares expected to actively trade in Friday's session are Vertex Pharmaceuticals Inc. (VRTX), Air Methods Corp. (AIRM) and International Business Machines Corp. (IBM). Vertex Pharmaceuticals said data from a mid-stage trial showed significant improvements in lung function among adults with the... More...>> |
